Thu, Oct 2, 2014, 3:46 AM EDT - U.S. Markets open in 5 hrs 44 mins

Recent

% | $
Quotes you view appear here for quick access.

Financial News From Zacks Small Cap Research

  • S&W Seed (SANW) reported its fourth quarter and full year results on Sept. 29, 2014. Revenue was slightly below our estimate of $20 million at $19.6 million and, due to a reserve taken against accounts receivable plus some unanticipated labor costs, SG&A was above our estimate. Due to a glut of seed from the record 2013 …

  • TNXP: Tonix reports results from the Phase 2b/3 BESTFIT trial Zacks Small Cap Research - Mon, Sep 29, 2014 7:00 PM EDT

    On September 29, 2014, Tonix Pharmaceuticals (TNXP) announced top line results for the Phase 2b/3 BESTFIT trial. The study did not achieve statistical significance in the primary efficacy endpoint of change in average daily pain score at week 12 (p=0.086 by mixed-effect model repeated measure analysis, p=0.172 by jump-to-control, …

  • SANW: New exclusive distribution agreement in Pakistan. Zacks Small Cap Research - Fri, Sep 26, 2014 12:30 PM EDT

    By Ian Gilson, PhD, CFA NASDAQ:SANW The company announced on September 25, 2014 that it has entered into a distribution agreement with Maxim International (Private) Limited for Maxim to be the exclusive ...

  • LPCN: Positive Phase 3 Data Makes Lipocine Shares Soar Zacks Small Cap Research - Thu, Sep 25, 2014 3:00 PM EDT

    On September 24, 2014 Lipocine, Inc. (LPCN) announced positive top-line results for the Study of Oral Androgen Replacement (“SOAR”) Phase 3 clinical trial. Overall, the study was a success, showing positive results with respect to the primary efficacy endpoints, no serious adverse events, and generally meeting FDA pre-specified …

  • Soligenix: A Low Risk, High Return Biotech Stock Zacks Small Cap Research - Tue, Sep 23, 2014 11:30 AM EDT

    On September 3, 2014, Soligenix (SNGX) entered into an asset purchase agreement with Hy Biopharma, Inc. Pursuant to the agreement, Soligenix acquired a novel orphan drug candidate, known as SGX301 (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL). As part of the acquisition, Soligenix acquired …

  • SNGX: Another Important Contract for Soligenix from NIAID Zacks Small Cap Research - Fri, Sep 19, 2014 12:45 PM EDT

    Earlier today, Soligenix (SNGX) announced that it has been awarded a contract valued at up to $24.7 million by the National Institute of Allergy and Infectious Diseases (NIAID), an division of the US Department of Health and Human Service's National Institutes of Health (NIH).   According to the company’s news release, …

  • CPKF: Raising 2014 and 2015 EPS Estimates Following the Second Quarter Zacks Small Cap Research - Fri, Sep 19, 2014 11:30 AM EDT

    We are raising our 2014 and 2015 diluted EPS estimates for Chesapeake Financial Shares, Inc. (CPKF) following a second quarter that was better than we had expected. The major reasons for the rise in our projections stems from: (1) a lower effective tax rate in 2014, reflecting a one-time tax adjustment and (2) for both …

  • ROSG: Rosetta Genomics Reports Better Than Expected Financial Results for 1H2014 Zacks Small Cap Research - Fri, Sep 19, 2014 9:00 AM EDT

    On Sep 17, 2014, Rosetta Genomics (ROSG) reported better than expected financial results for the six months ended June 30, 2014. During the first half of 2014 the Company raised net proceeds of $3.0 million from the sale of approximately 750,000 ordinary shares through the previously announced Sales Agreements with Cantor …

  • Does TapImmune Have What It Takes To Succeed? Zacks Small Cap Research - Thu, Sep 18, 2014 10:30 AM EDT

    TapImmune (TPIV) is a clinical stage immunotherapy company focused on the development of treatments for cancer and infectious diseases. The company’s technology is designed to enhance the body’s ability to recognize these diseases. TapImmune’s lead candidate is a novel antigen vaccine based off the research of Dr. Keith …

  • PURE: Out-Licensing Will Generate Additional Revenue for PURE Zacks Small Cap Research - Thu, Sep 18, 2014 9:00 AM EDT

    By Grant Zeng, CFA OTC:PURE On August 19, 2014, PURE Bioscience (OTC:PURE) announced that, it has entered into a license and distribution agreement with UK-based Research Instruments Limited.   As part ...

  • Virtual Piggy (VPIG): PayPal For the Tween and Teen Market Zacks Small Cap Research - Wed, Sep 17, 2014 4:05 PM EDT

    Virtual Piggy (VPIG) offers what management believes is the only online payment solution that complies with U.S. The product, Oink, allows parents to impose parental controls and monitor their children’s online and mobile spending, a feature that we believe will be attractive to parents. Now, having reached the one million …

  • JAMN: Zacks recaps Jammin Java’s FY2Q report and maintains Outperform rating Zacks Small Cap Research - Wed, Sep 17, 2014 12:30 PM EDT

    Jammin Java (JAMN) d/b/a Marley Coffee reported financial results for the second fiscal quarter ending July 30, 2014. Gross income increased 4.9% to $495,159 compared with $472,079 primarily due to increased sales, but offset by gross profit margin compression of 558 basis points (bps) from 29.4% to 23.8%, primarily due …

  • PBSV Continues To Generate Huge Cash Flow Zacks Small Cap Research - Tue, Sep 16, 2014 3:45 PM EDT

    By Brian Marckx, CFA OTC:PBSV Fiscal Q3 2014 Results: Revenue Softness Continues But Still Generating Tons of Cash…   Pharma-Bio Serv (OTC:PBSV) reported financial results for the fiscal third quarter ...

  • DMPI: Higher Doses Will Increase the Chance of Success for VAL-083 Zacks Small Cap Research - Tue, Sep 16, 2014 8:00 AM EDT

    On August 19, 2014, DelMar (DMPI) filed a protocol amendment with the FDA to increase the doses of VAL-083 up to 60mg/m2. The Company already initiated the treatment of patients at 50mg/m2 in the Phase I/II clinical trial for glioblastoma. DelMar is now delivering higher doses compared to previous glioblastoma clinical …

  • VNRX: Data Supports NuQ Utility in Colon Cancer Zacks Small Cap Research - Mon, Sep 15, 2014 9:35 AM EDT

    Data From Largest Sample Base To-Date Supports Earlier Findings of NuQ Utility for Colon Cancer: As we noted in our previous update, we had anticipated that announcement of data from the initial 1,000 patients in the retrospective colon cancer study being done at Hvidovre Hospital (Denmark) would be forthcoming.  That …

  • TAIPF: Zacks initiates coverage of Taipan Resources with an Outperform rating Zacks Small Cap Research - Mon, Sep 15, 2014 9:00 AM EDT

    Zacks has initiated coverage of Taipan Resources (TAIPF) (TPN.V) with an Outperform rating and a price target of CDN $0.87 for TPN.V and US $0.78 for TAIPF. Taipan is an oil & gas exploration company with interests in two onshore blocks in Kenya: a 30% participating interest in Block 2B and a 20% participating interest …

  • CONX: Record Revenue in Q4 and Fiscal 2014 Zacks Small Cap Research - Thu, Sep 11, 2014 9:30 AM EDT

    Corgenix Medical (CONX) filed their 10-K for the fiscal fourth quarter and year ending June 30, 2013.  Q4 revenue was just about dead-on with our number, gross margin beat handily and opex came in higher - the net result was net income slightly below our number - although the difference not overly meaningful.   Q4 revenue …

  • SANW: Company to enter a significant new alfalfa market through a JV in Argentina Zacks Small Cap Research - Thu, Sep 11, 2014 7:00 AM EDT

    S&W Seed (SANW) has announced that it will form a fifty-fifty joint venture with Bioceres S.A. in Argentina to develop and sell GMO and proprietary alfalfa seeds in Argentina. At this time there are no sales of GMO alfalfa in Argentina. Currently the members are not growing or marketing alfalfa through Bioceres and the …

  • SNWV: DMC Recommendation Causes 4+ Month Delay Zacks Small Cap Research - Wed, Sep 10, 2014 11:15 AM EDT

    By Brian Marckx, CFA OBB:SNWV Enrollment Increased From 90 to 130 Patients, Causes At Least 4 Month Delay This morning (9/10/2014) SANUWAVE (OBB:SNWV) announced the Data Monitoring Committee (DMC) overseeing ...

  • SANW: The company intends to patent improved stevia varieties. Zacks Small Cap Research - Tue, Sep 9, 2014 4:05 PM EDT

    By Ian Gilson, PhD, CFA NASDAQ:SANW The company has announced that it will apply for patents on stevia varieties that have improved glycoside profiles (including increased concentrations of Reb A.) and ...

  • You're Invited - Zacks Healthcare Meet-Up Zacks Small Cap Research - Mon, Sep 8, 2014 9:30 AM EDT

    By Zacks Small-Cap Research NASDAQ:TNXP NYSE:CUR OTC:AMBS On September 8, 2014, Zacks Small-Cap Research will host its  First Annual Healthcare Meet-Up  at the Whiskey Blue Bar in New York City. Investors ...

  • Soligenix (SNGX) is a clinical stage biopharmaceutical company focused on the development of therapeutics for the treatment of inflammatory diseases, cancer and biodefense applications. On September 5th, 2014, the company announced the acquisition of all intellectual property, preclinical and clinical data for SGX301 (synthetic …

  • ICOTF: More Data From iDEAL Coming In Q4 From iCo Therapeutics Zacks Small Cap Research - Fri, Sep 5, 2014 9:30 AM EDT

    On August 29, 2014, iCo Therapeutics (ICOTF) (ICO.V) announced financial results for the second quarter ending June 30, 2014. Loss for the quarter also included a paper loss of $0.327 million in the company’s investment in Immune Pharmaceuticals (IMNP). As of June 30, 2014, iCo Therapeutics owns 654,486 million shares …

  • LMD.V: Increasing Price Target As Revenue Expected To Ramp Zacks Small Cap Research - Fri, Sep 5, 2014 8:30 AM EDT

    LED Medical (LEDIF) (LMD.V) filed their Q2 2014 financials for the period ending June 30, 2014.  Similar to Q1 of this year, revenue increased significantly on both a sequential and yoy basis and was again well ahead of our estimate.  And while the company did not provide specifics relative to the impetus for the continued …

  • Although most of the company's (SANW) US acreage is irrigated, especially in the Central Valley of California, the current drought and well above average temperatures in the Western USA are affecting dairy herds and hay exports from California are below year ago levels according the Hoyt Report. The climate changes may …

  • AMBS: Amarantus Investor Call Highlights Clinical And Commercial Milestones Zacks Small Cap Research - Wed, Sep 3, 2014 2:30 PM EDT

    On August 27, 2014, Amarantus BioScience (AMBS) reported financial results for the second quarter 2014. We agree with this hypothesis. 

  • Jammin Java (JAMN) d/b/a Marley Coffee continues to execute on a growth strategy based on multi-channel geographic penetration and brand awareness-based volume growth.  Over the last three months, the company issued four press releases enumerating eight new or expanded domestic retail distribution relationships. In addition, …

  • On September 2, 2014, the company announced promising results from a pilot study in non-human primates with its ricin toxin vaccine, RiVaxTM. The study, which exposed animals to 3-5 times the lethal dose of aerosolized ricin toxin, resulted in complete protection and a highly statistically significant survival benefit …

  • Sorrento Therapeutics (SRNE) is a clinical stage biopharmaceutical company focused on developing novel treatments for cancer and associated pain. On August 26th, 2014, the company announced it was awarded a Phase 1 Small Business Technology Transfer (SBIR) grant from the National Heart, Lung, and Blood Institute (NHBLI) …

  • Corporate Resource Services (CRRS) has reported results for its 1Q 2014, which we believe is another step towards the company’s regaining compliance with the Nasdaq listing requirements. Management expects to meet the deadline.

  • GLSO: GlassesOff To Start Marketing Its App Soon Zacks Small Cap Research - Wed, Aug 27, 2014 3:20 PM EDT

    The company reported revenues of $0.018 million and had a net loss of $1.329 million, or $0.02 per share. GlassesOff used $0.849 million in cash to fund operations in the second quarter and the company exited June 2014 with approximately $4.734 million in cash on the books. We believe that the current cash position should …

  • NWBO Reports Second Quarter Financials Zacks Small Cap Research - Wed, Aug 27, 2014 12:30 PM EDT

    The increase was primarily attributable to costs associated with launching, manufacturing for, and conducting (including CRO costs) the Phase III DCVax-L trial in Europe and the Phase I/II DCVax-Direct, which were just beginning as of this period last year, as well as expansion of the Company’s German subsidiary and its …

  • Advaxis (ADXS), a clinical stage biopharmaceutical company, announced on August 25, 2014, that it has entered into a collaboration with Merck & Co to evaluate an experimental drug combination for advanced stage prostate cancer. The study will use Advaxis’s ADXS-PSA immunotherapy alone or in combination with Merck’s PD-1 …

  • OMBP: Omni Bio Executing On Development Plan Zacks Small Cap Research - Tue, Aug 26, 2014 11:50 AM EDT

    On August 15, 2014 Omni Bio Pharma (OMBP) reported financial results for the three month period ending June 30, 2014 and filed its From 10-Q with the U.S. Omni Bio did not report any revenues during the first quarter fiscal 2015. Both line-items were slightly below expectations as the company focuses on keeping operations …

  • ULUR: Analysis of ULURU, Inc. Second Quarter Financial & Business Update Zacks Small Cap Research - Fri, Aug 22, 2014 3:00 PM EDT

    On August 14, 2014, ULURU, Inc. (ULUR) reported financial results and filed its Form 10-Q for the second quarter ending June 30, 2014. ULURU classifies countries into four sizes:

  • NWTR: New Western Energy reports revenue gain of 840% and marked reduction in loss. Zacks Small Cap Research - Thu, Aug 21, 2014 10:00 AM EDT

    By Ian Gilson, PhD, CFA OTC:NWTR The company (OTC:NWTR) announced its second quarter results on August 18, 2014. Revenue was close to our estimate and increased by 840% Y/Y and 57% from the first quarter. ...

  • FPMI: Positive CardioPET Data. Q2 Results Zacks Small Cap Research - Wed, Aug 20, 2014 1:05 PM EDT

    Q2 operating expenses were ~$1.2M, slightly better than our $1.5M estimate.  We continue to expect operating expenses to increase with clinical trials progression.  Q2 net loss and EPS, excluding non-cash securities and derivative related items, were $1.4M and ($0.05), compared to our $1.7M and ($0.06) estimates.  Cash …

  • Zacks Small Cap Research Upgrades CUR Media to a BUY Zacks Small Cap Research - Wed, Aug 20, 2014 11:55 AM EDT

    OBB:CURM Zacks Analyst Lisa Thompson, has upgraded CUR Media (OBB:CURM) to a buy rating due to increased float and attractive valuation: PLEASE CLICK HERE FOR A FULL COPY OF THE RESEARCH REPORT. SUBSCRIBE ...

  • AEMD: Q1 Update, Revived Attention on Ebola Zacks Small Cap Research - Wed, Aug 20, 2014 9:15 AM EDT

    Aethlon Medical (AEMD) filed their 10-Q for the fiscal first quarter ending 6/30/2014.  Highlights in the quarter include further progress in cleaning up the balance sheet via the conversion of non-performing debt to equity and revived attention as to the potential utility of Hemopurifier in the treatment of pandemic threats, …

  • BPTH: Bio-Path Reports 2Q2014 Financials Zacks Small Cap Research - Tue, Aug 19, 2014 11:10 AM EDT

    On August 18, Bio-Path Holdings (BPTH) announced operational and financial results for the second quarter ended June 30, 2014. R&D expenses were $0.52 million for 2Q14, compared to $0.19 million for 2Q13, an increase of $361,004 primarily due to an increase of $233,985 in drug material expense for use in the clinical trial, …

  • Last week, Labor Smart (LTNC) announced results for 2Q 2014, with revenue of $6.43 million up 59.5% year-over-year. As a result, Labor Smart’s 2Q 2014 gross margin came in at 21.2%, a more than 600 basis point expansion year-over-year. The company’s goal is to drive further gross margin improvements. This compares to …

  • This offers a better access to Canadian capital markets and investors.  On May 13, 2014, Tribute entered into an exclusive license agreement with Faes Farma, S.A. (“Faes”), a Spanish pharmaceutical company, for the exclusive rights to sell Bilastine (inclusive of prescription and non-prescription for adults and pediatric …

  • GRDH: Guardian 8 reports 2Q – Awaiting catalyst for large-scale adoption of Pro V2 Zacks Small Cap Research - Mon, Aug 18, 2014 3:00 PM EDT

    On August 14, 2014, Guardian 8 Holdings (GRDH) reported financial results for the second quarter ending June 30, 2014. Guardian 8 generated revenues of $13,967 from the sales of G8 Pro V2 devices, which continue to be sold in small batches for modest deployments and evaluation. In mid-April, Guardian 8 announced that …

  • CTTC: Q2 Results. Court Ruling Favors Calmare Reimbursement Zacks Small Cap Research - Mon, Aug 18, 2014 2:15 PM EDT

    Q2 revenue of $332k compares to our $309k estimate and includes $316k from the sale of four Calmare units during the quarter.  Three units were sold to the private sector and one to the U.S. military.  Compared to Q2 2013 product sales and total revenue increased by 132% and 121%, respectively.  Through the first six months …

  • NHC.TO: Northstar Healthcare reports 2Q; Zacks raises target to $2.25 Zacks Small Cap Research - Mon, Aug 18, 2014 9:45 AM EDT

    On August 14, 2014, Northstar Healthcare (NHC.TO) reported financial results for the second quarter ending June 30, 2014. Net patient service revenue increased 158% to $15.11 million compared to $5.86 million in the second quarter of 2013, primarily due to increases in case volume, which was driven by marketing campaigns …

  • NHC.TO: Northstar Healthcare reports 2Q; Zacks raises target to $2.35 Zacks Small Cap Research - Mon, Aug 18, 2014 9:00 AM EDT

    On August 14, 2014, Northstar Healthcare (NHC.TO) reported financial results for the second quarter ending June 30, 2014. Net patient service revenue increased 158% to $15.11 million compared to $5.86 million in the second quarter of 2013, primarily due to increases in case volume, which was driven by marketing campaigns …

  •  On August 12, 2014, Arrowhead Research Corporation (ARWR) announced financial results for its fiscal 2014 third quarter ended June 30, 2014 and provided an update on the Phase IIa study of ARC-520.

  • PBIO: Product and Services Revenue for 2Q14 Continued to Grow Zacks Small Cap Research - Mon, Aug 18, 2014 7:00 AM EDT

    Sales of consumables were $48,417 for 2Q14, compared to $26,034 for the same period in 2013, an increase of 86%. Total revenue for 2Q14 was $307,464, compared to $357,736 for the same period in 2013, a 14% decrease. Sales of consumables were $103,029 for the six months ended June 30, 2014 compared to $53,258 for the same …

  • By Ann Heffron, CFA, CPA NASDAQ:QCRH Compared to the year-ago quarter, QCR Holdings, Inc.’s (NASDAQ:QCRH) second quarter net earnings after preferred stock dividends rose 12% to $3.6 million from $3.2 ...

  • ENSV: Zack raises target on Enservco on details of capacity expansion’s timetable Zacks Small Cap Research - Fri, Aug 15, 2014 9:00 AM EDT

    In the 10-Q and conference call, management provided an update on Phase 2 of the company’s 2014 capacity expansion plan, along with details of the new $40 million credit facility with PNC Bank, a fraction of will fund Phase 2. The new frac-water "mega" heaters have twice the capacity of the company's legacy frac-water …

Next >>